SBRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sabra Health Care REIT Inc (SBRA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has some positive technical indicators and analyst support, the financial performance shows declining profitability, and the stock's near-term trend suggests potential downside. Given the user's preference for long-term investment, it is better to wait for clearer growth signals or improved financial performance before committing funds.
The technical indicators are mixed but lean slightly positive. The MACD histogram is positive and expanding, suggesting bullish momentum. The RSI is neutral, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock's candlestick pattern indicates a 60% probability of a slight decline in the next day, week, and month.
Analysts have raised price targets recently, with Citi and BofA maintaining Buy ratings and targets of $24 and $23, respectively. The healthcare REIT sector is benefiting from increased demand driven by an aging U.S. population.
The company's Q4 2025 financials show a significant decline in net income (-41.70% YoY) and EPS (-42.11% YoY), despite a 16.21% increase in revenue. Gross margin also dropped by 8.17% YoY. Additionally, the stock's short-term trend indicates potential downside.
In Q4 2025, revenue increased by 16.21% YoY to $211.9M, but net income dropped by 41.70% YoY to $27.2M. EPS fell by 42.11% YoY to $0.11, and gross margin declined by 8.17% to 63.75%. These metrics indicate declining profitability despite revenue growth.
Analysts are cautiously optimistic. Citi and BofA have Buy ratings with price targets of $24 and $23, respectively. UBS, Cantor Fitzgerald, and Truist have Neutral ratings with price targets around $21. Analysts generally see potential in the healthcare REIT sector but note challenges in profitability and occupancy.
